Literature DB >> 24116939

Development of a high-throughput screening-compatible cell-based functional assay to identify small molecule probes of the galanin 3 receptor (GalR3).

James Robinson1, Anthony Smith, Emmanuel Sturchler, Sahba Tabrizifard, Theodore Kamenecka, Patricia McDonald.   

Abstract

The galanin 3 receptor (GalR3) belongs to the large G protein-coupled receptor (GPCR) family of proteins. GalR3 and two other closely related receptors, GalR1 and GalR2, together with their endogenous ligand galanin, are involved in a variety of physiological and pathophysiological processes. GalR3 in particular has been strongly implicated in addiction and mood-related disorders such as anxiety and depression. It has been the target of many drug discovery programs within the pharmaceutical industry, but despite the significant resources and effort devoted to discovery of galanin receptor subtype selective small molecule modulators, there have been very few reports for the discovery of such molecules. GalR3 has proven difficult to enable in cell-based functional assays due to its apparent poor cell surface expression in recombinant systems. Here, we describe the generation of a modified GalR3 that facilitates its cell surface expression while maintaining wild-type receptor pharmacology. The modified GalR3 has been used to develop a high-throughput screening-compatible, cell-based, cAMP biosensor assay to detect selective small molecule modulators of GalR3. The performance of the assay has been validated by challenging it against a test library of small molecules with known pharmacological activities (LOPAC; Sigma Aldrich). This approach will enable identification of GalR3 selective modulators (chemical probes) that will facilitate dissection of the biological role(s) that GalR3 plays in normal physiological processes as well as in disease states.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24116939      PMCID: PMC3804082          DOI: 10.1089/adt.2013.526

Source DB:  PubMed          Journal:  Assay Drug Dev Technol        ISSN: 1540-658X            Impact factor:   1.738


  38 in total

Review 1.  Galanin receptor subtypes.

Authors:  T A Branchek; K E Smith; C Gerald; M W Walker
Journal:  Trends Pharmacol Sci       Date:  2000-03       Impact factor: 14.819

2.  Cellular dielectric spectroscopy: a powerful new approach to label-free cellular analysis.

Authors:  Gary J Ciambrone; Vivian F Liu; Deborah C Lin; Ryan P McGuinness; Gordon K Leung; Simon Pitchford
Journal:  J Biomol Screen       Date:  2004-09

Review 3.  Mechanisms of GABAB receptor exocytosis, endocytosis, and degradation.

Authors:  Dietmar Benke
Journal:  Adv Pharmacol       Date:  2010

4.  Restricted distribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system.

Authors:  Françoise Mennicken; Cyrla Hoffert; Manon Pelletier; Sultan Ahmad; Dajan O'Donnell
Journal:  J Chem Neuroanat       Date:  2002-11       Impact factor: 3.052

5.  Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus-maze.

Authors:  Andrew Holmes; Jefferson W Kinney; Craige C Wrenn; Qian Li; Rebecca J Yang; Li Ma; Janani Vishwanath; Maria C Saavedra; Caitlin E Innerfield; Arie S Jacoby; John Shine; Tiina P Iismaa; Jacqueline N Crawley
Journal:  Neuropsychopharmacology       Date:  2003-04-09       Impact factor: 7.853

6.  Galanin-R1 and -R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity.

Authors:  T C Burazin; J A Larm; M C Ryan; A L Gundlach
Journal:  Eur J Neurosci       Date:  2000-08       Impact factor: 3.386

7.  Large reduction in the number of galanin-immunoreactive cells in pancreatic islets of diabetic rats.

Authors:  E Adeghate; A S Ponery
Journal:  J Neuroendocrinol       Date:  2001-08       Impact factor: 3.627

Review 8.  The participation of galanin in pain processing at the spinal level.

Authors:  Hong-Xiang Liu; Tomas Hökfelt
Journal:  Trends Pharmacol Sci       Date:  2002-10       Impact factor: 14.819

Review 9.  Galanin and addiction.

Authors:  M R Picciotto
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

Review 10.  Galanin, galanin receptors and drug targets.

Authors:  K Mitsukawa; X Lu; T Bartfai
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

View more
  7 in total

1.  Identification of Novel, Structurally Diverse, Small Molecule Modulators of GPR119.

Authors:  Ainhoa Nieto; Virneliz Fernández-Vega; Timothy P Spicer; Emmanuel Sturchler; Pramisha Adhikari; Nicole Kennedy; Sean Mandat; Peter Chase; Louis Scampavia; Thomas Bannister; Peter Hodder; Patricia H McDonald
Journal:  Assay Drug Dev Technol       Date:  2018-07       Impact factor: 1.738

Review 2.  Current approaches for the discovery of drugs that deter substance and drug abuse.

Authors:  Adam Yasgar; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2014-09-24       Impact factor: 6.098

3.  Alterations in the neuropeptide galanin system in major depressive disorder involve levels of transcripts, methylation, and peptide.

Authors:  Swapnali Barde; Joelle Rüegg; Josée Prud'homme; Tomas J Ekström; Miklos Palkovits; Gustavo Turecki; Gyorgy Bagdy; Robert Ihnatko; Elvar Theodorsson; Gabriella Juhasz; Rochellys Diaz-Heijtz; Naguib Mechawar; Tomas G M Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-09       Impact factor: 11.205

Review 4.  Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.

Authors:  David Weinshenker; Philip V Holmes
Journal:  Brain Res       Date:  2015-11-20       Impact factor: 3.252

5.  Development of functionally selective, small molecule agonists at kappa opioid receptors.

Authors:  Lei Zhou; Kimberly M Lovell; Kevin J Frankowski; Stephen R Slauson; Angela M Phillips; John M Streicher; Edward Stahl; Cullen L Schmid; Peter Hodder; Franck Madoux; Michael D Cameron; Thomas E Prisinzano; Jeffrey Aubé; Laura M Bohn
Journal:  J Biol Chem       Date:  2013-11-01       Impact factor: 5.157

6.  Intranasal Delivery of a Methyllanthionine-Stabilized Galanin Receptor-2-Selective Agonist Reduces Acute Food Intake.

Authors:  Anneke Kuipers; Márta Balaskó; Erika Pétervári; Andreas Koller; Susanne M Brunner; Gert N Moll; Barbara Kofler
Journal:  Neurotherapeutics       Date:  2021-12-02       Impact factor: 7.620

7.  Lack of Galanin 3 Receptor Aggravates Murine Autoimmune Arthritis.

Authors:  Bálint Botz; Ágnes Kemény; Susanne M Brunner; Felix Sternberg; Janka Csepregi; Attila Mócsai; Erika Pintér; Jason J McDougall; Barbara Kofler; Zsuzsanna Helyes
Journal:  J Mol Neurosci       Date:  2016-03-03       Impact factor: 2.866

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.